Skip to main
ARDX
ARDX logo

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 50%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx Inc has demonstrated significant financial growth with Q4 2024 net sales for IBSRELA reaching $53.8 million, representing a 32.5% increase from Q3 2024, and XPHOZAH sales totaling $57.2 million, marking an 11.1% quarterly growth, contributing to a total of $160.9 million in its first full year of XPHOZAH sales. The company is optimistic about future sales projections, with estimated 2025 net sales for IBSRELA set at $241.2 million and a projected annual growth of approximately 52% - 58%, alongside a moderate growth rate for XPHOZAH sales. Ardelyx is also implementing new patient outreach initiatives and expanding its sales team, enhancing access to treatments and potentially supporting long-term revenue growth.

Bears say

Ardelyx Inc. faces several significant challenges that contribute to a negative outlook for its stock, particularly with respect to its product XPHOZAH; total weekly scripts are projected to remain stagnant at around 750, raising concerns about its market penetration and growth trajectory. The company reported a substantial FY2024 net loss of $39.1 million, accompanied by high operating costs, notably $258.7 million in SG&A expenses, which could hinder financial sustainability and viability going forward. Furthermore, potential risks such as market size limitations, competition, and the possibility of regulatory issues or clinical trial failures introduce substantial uncertainty regarding the future performance of its products, exacerbating the volatility typically associated with biotech investments.

Ardelyx (ARDX) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 50% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Buy based on their latest research and market trends.

According to 14 analysts, Ardelyx (ARDX) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.